Amanta Healthcare: Should You Buy, Hold, or Sell Right Now?

Amanta Healthcare share price is trading close to its 52-week high of Rs 205.57, with Amanta Healthcare share price around Rs 198 on the NSE, more than double its 52-week low of Rs 92. With a large capacity expansion weighing modestly on near-term margins in Q1 FY27, investors are asking whether this sterile injectable manufacturer is a stock to buy near its highs, a hold, or a sell.

This Amanta Healthcare stock analysis walks through the Q1 FY27 numbers, the ongoing capacity expansion, valuation against the pharma sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and investor communications.

Click Here – Get Free Investment Predictions

About Amanta Healthcare

Before deciding on Amanta Healthcare share price, it helps to understand the underlying business. Amanta Healthcare Ltd. manufactures sterile injectable pharmaceutical products, including large volume parenterals and small volume parenterals, serving hospitals and healthcare providers.

The company is undertaking a significant Rs 150 crore capacity expansion, including its SteriPort facility and new small volume parenteral lines, aimed at more than doubling capacity and driving future revenue growth, though this investment phase has introduced some near-term cost pressure.

Amanta Healthcare Share Price Today: Key Levels

The table below summarises where Amanta Healthcare share price stands right now against its recent trading range and market value.

Metric	Value
Amanta Healthcare CMP (NSE)	Rs 197.91
Amanta Healthcare CMP (BSE)	Rs 198.65
52-Week High	Rs 205.57
52-Week Low	Rs 92.00
Market Capitalisation	Approximately Rs 756 crore

Amanta Healthcare share price is trading close to its 52-week high, having more than doubled from its 52-week low, reflecting investor confidence in the company's capacity expansion story.

Check the Univest Screener for Live Stock Data

Amanta Healthcare Financial Performance

The Amanta Healthcare share price trend is closely tied to how these numbers evolve each quarter. Amanta Healthcare reported Q1 FY27 (June 2026 quarter) revenue of Rs 68.8 crore, up 5.4 percent year on year from Rs 65.3 crore, with EBITDA of Rs 14.5 crore, down slightly from Rs 14.9 crore, as EBITDA margin contracted to 21.13 percent from 22.81 percent. Net profit dipped to Rs 3.3 crore from Rs 3.5 crore, with the decline primarily driven by higher finance costs associated with a new solar term loan supporting the company's captive power initiative.

The company is advancing a Rs 150 crore capacity expansion, including its SteriPort Line 3 and new small volume parenteral facility, targeted for commissioning in Q2 FY27, with management guiding toward peak revenues of Rs 425 crore by FY28 once these facilities are fully operational.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	Rs 68.80 crore	Rs 3.30 crore	+5.4% revenue; profit dipped slightly on higher finance costs

Valuation Check: Is Amanta Healthcare Share Price Expensive?

Any view on Amanta Healthcare share price should start from these valuation multiples. Amanta Healthcare share price currently reflects a price to earnings ratio of about 51.53 times trailing earnings, roughly in line with the broader pharmaceutical sector average of roughly 50.8 times. The price to book ratio stands near 3.4 times, with return on equity at 7.46 percent.

Debt to equity of 1.11 is elevated, reflecting the company's ongoing capacity expansion funding. Given the significant capacity investment underway, this roughly in-line valuation reflects the market's expectation that the expansion will drive meaningfully higher revenue once commissioned.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Amanta Healthcare share price. Amanta Healthcare share price is currently positioned just below its 52-week high of Rs 205.57, more than double its 52-week low of Rs 92, reflecting a very strong overall run over the past year. A stock trading this close to its high, despite a slight near-term profit dip tied to capacity expansion costs, typically signals the market looking past temporary investment-phase pressure toward future growth.

Trading volumes remain moderate, so investors should track Amanta Healthcare share price alongside the commissioning progress of the SteriPort and SVP facilities in coming quarters, rather than reacting to the slight Q1 FY27 profit dip alone at these technical levels.

Download the Univest iOS App or Univest Android App to track Amanta Healthcare's live price and technical levels.

Shareholding Pattern

Shifts here can influence Amanta Healthcare share price more than headline news on some sessions. Amanta Healthcare is a promoter-led sterile injectable pharmaceutical manufacturer undertaking a significant capacity expansion. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Amanta Healthcare

• Significant capacity expansion underway: The Rs 150 crore investment in SteriPort and new SVP lines is targeted to more than double capacity and support peak revenue of Rs 425 crore by FY28.
• Continued revenue growth: Q1 FY27 revenue still grew 5.4 percent year on year even amid the capacity investment phase.
• Strong stock performance over the past year: The stock has more than doubled from its 52-week low, reflecting investor confidence in the expansion story.

Risks and Factors to Watch

• Near-term margin pressure from expansion costs: EBITDA margin contracted and profit dipped slightly due to higher finance costs tied to the capacity expansion, a trend that could continue until the new facilities are commissioned.
• Commissioning delay risk: The SteriPort Line 3 has already faced a four to five month delay, and further delays could push back the expected revenue benefits.
• Elevated leverage from expansion funding: A debt to equity ratio of 1.11 reflects the capital being deployed for the expansion, adding financial risk during the investment phase.
• Working capital and input cost volatility: Sterile product manufacturing involves long working capital cycles and exposure to polymer input cost volatility.

Amanta Healthcare Share Price Target: What the Data Suggests

Until then, Amanta Healthcare share price remains best tracked through live, verified data rather than a single fixed number. Amanta Healthcare does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company investing significantly in capacity expansion, trading roughly in line with the pharma sector near its 52-week high.

Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.

Amanta Healthcare: Should You Buy, Hold, or Sell Right Now?

This is the core question behind Amanta Healthcare share price right now. The Amanta Healthcare buy or sell decision depends on whether the SteriPort and SVP expansions deliver on schedule.

The case for buying: Investors who believe in the company's capacity expansion story and are comfortable with near-term margin pressure during the investment phase may find the current level, near its 52-week high, worth considering.

The case for holding: Existing shareholders who already track Amanta Healthcare's expansion progress may prefer to stay invested through the commissioning phase.

The case for waiting: Investors wanting to see the new facilities successfully commissioned and contributing to revenue before committing fresh capital may prefer to wait for that confirmation.

Weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.

Conclusion

Amanta Healthcare share price reflects a sterile injectable pharmaceutical manufacturer investing significantly in capacity expansion, with Q1 FY27 profit dipping slightly on higher finance costs even as revenue continued to grow, trading close to its 52-week high. This article is for informational purposes and not a personalised investment recommendation.

Q1. Is Amanta Healthcare a good stock to buy right now?

Ans. Amanta Healthcare's Q1 FY27 profit dipped slightly to Rs 3.3 crore due to higher finance costs tied to its Rs 150 crore capacity expansion, even as revenue grew 5.4 percent. This suits investors who believe in the expansion's targeted peak revenue of Rs 425 crore by FY28.

Q2. What is the Amanta Healthcare share price today?

Ans. Amanta Healthcare share price is trading around Rs 198 on the NSE, close to its 52-week high of Rs 205.57. The stock's 52-week low is Rs 92.

Q3. What is the Amanta Healthcare share price target?

Ans. Amanta Healthcare does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.

Q4. What does Amanta Healthcare manufacture?

Ans. Amanta Healthcare manufactures sterile injectable pharmaceutical products, including large volume parenterals and small volume parenterals, serving hospitals and healthcare providers.

Q5. What is Amanta Healthcare's capacity expansion plan?

Ans. Amanta Healthcare is investing Rs 150 crore in capacity expansion, including its SteriPort Line 3 and a new small volume parenteral facility, targeted for commissioning in Q2 FY27, aiming for peak revenue of Rs 425 crore by FY28.

Q6. What is Amanta Healthcare's market capitalisation and PE ratio?

Ans. Amanta Healthcare has a market capitalisation of approximately Rs 756 crore and trades at a price to earnings ratio of about 51.53 times, roughly in line with the pharmaceutical sector average PE of roughly 50.8 times.